Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
Eric L. Simpson, Jonathan I. Silverberg, Jacob P. Thyssen, Manuelle Viguier, Diamant Thaçi, Marjolein de Bruin-Weller, Stephan Weidinger, Gary Chan, Marco DiBonaventura, Pinaki Biswas, Claire Feeney, Christopher Koulias*, Michael J. Cork
Untersuchen Sie die Forschungsthemen von „Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial“. Zusammen bilden sie einen einzigartigen Fingerprint.